Risk and adverse outcomes of fractures in patients with Parkinson’s disease: two nationwide studies

Osteoporosis International

Volumn 26, Issue 6, 2015, Pages 1723-1732

  Huang, Y F ^a   Cherng, Y G ^a,b   Hsu, S P C ^c,d   Yeh, C C ^e,f   Chou, Y C ^e   Wu, C H ^g   Chen, T L ^b,h   Liao, C C ^b,h,i  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d UNIVERSITY OF VIRGINIA   (United States)

^e CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^f UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^g NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^h TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

ⁱ CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Fracture; Mortality; Parkinson s disease

Indexed keywords

ALENDRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID;

ADULT; ADVERSE OUTCOME; AGE; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; FRACTURE; HEALTH INSURANCE; HIGH RISK PATIENT; HOSPITAL PATIENT; HUMAN; INCIDENCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; OSTEOPOROSIS; PARKINSON DISEASE; PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEPTICEMIA; SEX RATIO; SUSCEPTIBLE POPULATION; TAIWAN; URINARY TRACT INFECTION; VERY ELDERLY; VULNERABLE POPULATION; AGE DISTRIBUTION; COMORBIDITY; COMPLICATION; FALLING; FRACTURES, BONE; HOSPITAL MORTALITY; PROGNOSIS; RISK FACTOR; SOCIOECONOMICS; STATISTICS AND NUMERICAL DATA;

ACCIDENTAL FALLS; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; COMORBIDITY; FEMALE; FRACTURES, BONE; HOSPITAL MORTALITY; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PARKINSON DISEASE; PROGNOSIS; RISK FACTORS; SEX DISTRIBUTION; SOCIOECONOMIC FACTORS; TAIWAN;

EID: 84931007863     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-015-3052-y     Document Type: Article

References (45)

1. Samii A, Nutt JG, Ransom BR (2004) Parkinson’s disease. Lancet 363:1783–1793
2. Pringsheim T, Jette N, Frolkis A, Steeves TD (2014) The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord 29:1583–1590
3. Nussbaum RL, Ellis CE (2003) Alzheimer’s disease and Parkinson’s disease. N Engl J Med 348:1356–1364
4. De Rijk MC, Launer LJ, Berger K et al (2000) Prevalence of Parkinson’s disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54:S21–S23
5. De Lau LM, Breteler MM (2006) Epidemiology of Parkinson’s disease. Lancet Neurol 5:525–535
6. Huse DM, Schulman K, Orsini L, Castelli-Haley J, Kennedy S, Lenhart G (2005) Burden of illness in Parkinson’s disease. Mov Disord 20:1449–1454
7. Berger K, Breteler MM, Helmer C et al (2000) Prognosis with Parkinson’s disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54:S24–S27
8. Pickering RM, Grimbergen YAM, Rigney U et al (2007) A meta-analysis of six prospective studies of falling in Parkinson’s disease. Mov Disord 22:1892–1900
9. Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301:513–521
10. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 22:465–475
11. Ström O, Borgström F, Kanis JA, Compston J, Cooper C, McCloskey EV, Jönsson B (2011) Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 6:59–155
12. Genever RW, Downes TW, Medcalf P (2005) Fracture rates in Parkinson’s disease compared with age- and gender-matched controls: a retrospective cohort study. Age Ageing 34:21–24
13. Pouwels S, Bazelier MT, de Boer A, Weber WE, Neef C, Cooper C, de Vries F (2013) Risk of fracture in patients with Parkinson’s disease. Osteoporos Int 24:2283–2290
14. Fink HA, Kuskowski MA, Taylor BC, Schousboe JT, Orwoll ES, Ensrud KE (2008) Association of Parkinson’s disease with accelerated bone loss, fractures and mortality in older men: the Osteoporotic Fractures in Men (MrOS) study. Osteoporos Int 19:1277–1282
15. Harris-Hayes M, Willis AW, Klein SE, Czuppon S, Crowner B, Racette BA (2014) Relative mortality in U.S. Medicare beneficiaries with Parkinson disease and hip and pelvic fractures. J Bone Joint Surg Am 96:e27
16. Chen YY, Cheng PY, Wu SL, Lai CH (2012) Parkinson’s disease and risk of hip fracture: an 8-year follow-up study in Taiwan. Parkinsonism Relat Disord 18:506–509
17. Melton LJ 3rd, Leibson CL, Achenbach SJ, Bower JH, Maraganore DM, Oberg AL, Rocca WA (2006) Fracture risk after the diagnosis of Parkinson’s disease: influence of concomitant dementia. Mov Disord 21:1361–1367
18. Johnell O, Melton LJ 3rd, Atkinson EJ, O'Fallon WM, Kurland LT (1992) Fracture risk in patients with parkinsonism: a population-based study in Olmsted County, Minnesota. Age Ageing 21:32–38
19. Sato Y, Kaji M, Tsuru T, Oizumi K (2001) Risk factors for hip fracture among elderly patients with Parkinson’s disease. J Neurol Sci 182:89–93
20. Schneider JL, Fink HA, Ewing SK, Ensrud KE, Cummings SR (2008) The association of Parkinson’s disease with bone mineral density and fracture in older women. Osteoporos Int 19:1093–1097
21. Liao CC, Shen WW, Chang CC, Chang H, Chen TL (2013) Surgical adverse outcomes in patients with schizophrenia: a population-based study. Ann Surg 257:433–438
22. Liao CC, Lin CS, Shih CC, Yeh CC, Chang YC, Lee YW, Chen TL (2014) Increased risk of fracture and postfracture adverse events in patients with diabetes: two nationwide population-based retrospective cohort studies. Diabetes Care 37:2246–2252
23. Liao CC, Chou YC, Yeh CC, Hu CJ, Chiu WT, Chen TL (2014) Stroke risk and outcomes in patients with traumatic brain injury: 2 nationwide studies. Mayo Clin Proc 89:163–172
24. Cheng CL, Kao YH, Lin SJ, Lee CH, Lai ML (2011) Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf 20:236–242
25. Court-Brown CM, Caesar B (2006) Epidemiology of adult fractures: a review. Injury 37:691–697
26. Guilley E, Herrmann F, Rapin CH, Hoffmeyer P, Rizzoli R, Chevalley T (2011) Socioeconomic and living conditions are determinants of hip fracture incidence and age occurrence among community-dwelling elderly. Osteoporos Int 22:647–653
27. Yang S, Nguyen ND, Center JR, Eisman JA, Nguyen TV (2014) Association between hypertension and fragility fracture: a longitudinal study. Osteoporos Int 25:97–103
28. Baker NL, Cook MN, Arrighi HM, Bullock R (2011) Hip fracture risk and subsequent mortality among Alzheimer’s disease patients in the United Kingdom, 1988–2007. Age Ageing 40:49–54
29. Dennison EM, Compston JE, Flahive J et al (2012) Effect of co-morbidities on fracture risk: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone 50:1288–1293
30. Hippisley-Cox J, Coupland C (2012) Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study. BMJ 344:e3427
31. Trimpou P, Odén A, Simonsson T, Wilhelmsen L, Landin-Wilhelmsen K (2011) High serum total cholesterol is a long-term cause of osteoporotic fracture. Osteoporos Int 22:1615–1620
32. Bhattacharjee S, Sambamoorthi U (2013) Co-occurring chronic conditions and healthcare expenditures associated with Parkinson’s disease: a propensity score matched analysis. Parkinsonism Relat Disord 19:746–750
33. Leibson CL, Maraganore DM, Bower JH, Ransom JE, O'brien PC, Rocca WA (2006) Comorbid conditions associated with Parkinson’s disease: a population-based study. Mov Disord 21:446–455
34. Kauppi M, Stenholm S, Impivaara O, Mäki J, Heliövaara M, Jula A (2014) Fall-related risk factors and heel quantitative ultrasound in the assessment of hip fracture risk: a 10-year follow-up of a nationally representative adult population sample. Osteoporos Int 25:1685–1695
35. Gerlach OH, Broen MP, van Domburg PH, Vermeij AJ, Weber WE (2012) Deterioration of Parkinson’s disease during hospitalization: survey of 684 patients. BMC Neurol 12:13
36. Gerlach OH, Winogrodzka A, Weber WE (2011) Clinical problems in the hospitalized Parkinson’s disease patient: systematic review. Mov Disord 26:197–208
37. Chou KL, Zamudio J, Schmidt P et al (2011) Hospitalization in Parkinson disease: a survey of National Parkinson Foundation Centers. Parkinsonism Relat Disord 17:440–445
38. Sato Y, Kikuyama M, Oizumi K (1997) High prevalence of vitamin D deficiency and reduced bone mass in Parkinson’s disease. Neurology 49:1273–1278
39. Sato Y, Iwamoto J, Honda Y (2011) Amelioration of osteoporosis and hypovitaminosis D by sunlight exposure in Parkinson’s disease. Parkinsonism Relat Disord 17:22–26
40. Invernizzi M, Carda S, Viscontini GS, Cisari C (2009) Osteoporosis in Parkinson’s disease. Parkinsonism Relat Disord 15:339–346
41. Gnädinger M, Mellinghoff HU, Kaelin-Lang A (2011) Parkinson’s disease and the bones. Swiss Med Wkly 141:w13154
42. Dobson R, Yarnall A, Noyce AJ, Giovannoni G (2013) Bone health in chronic neurological diseases: a focus on multiple sclerosis and parkinsonian syndromes. Pract Neurol 13:70–79
43. Lees AJ, Hardy J, Revesz T (2009) Parkinson’s disease. Lancet 373:2055–2066
44. Pouwels S, van Staa TP, Egberts AC, Leufkens HG, Cooper C, de Vries F (2009) Antipsychotic use and the risk of hip/femur fracture: a population-based case-control study. Osteoporos Int 20:1499–1506
45. Vestergaard P, Rejnmark L, Mosekilde L (2007) Fracture risk associated with parkinsonism and anti-Parkinson drugs. Calcif Tissue Int 81:153–161